ArticleScientific reports2025
Expression and purification of NS1 protein for designing a lateral flow assay-based aptamer-antibody.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lipopolysaccharide-Specific Aptasensor: A Spectroscopic Approach for Identifying Gram-Negative Bacteria.Analytical science advances · 2026Article
- Research Advances and Future Perspectives of Point-of-Care Detection Technologies and Biosensors for Mosquito-Borne Viruses.Biosensors · 2026Review
- Translational opportunities in aptamer and nanobody lateral flow assays within the WHO REASSURED framework.Sensors & diagnostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue fever, a mosquito-borne viral disease, presents with mild symptoms in most patients but is characterized by dengue hemorrhagic fever (DHF) in severe cases. Current diagnostic methods are expensive and take time to process. Diagnostic testing is currently limited, particularly in low-resource environments. In this work, we provide the development of a rapid diagnostic test for dengue using a lateral flow immunoassay (LFA) strip using an aptamer-antibody sandwich to detect the NS1 protein. The LFA includes an antibody capture zone and a conjugate pad with an aptamer linked to gold nanoparticles (AuNPs). A biotin-labeled complementary aptamer is immobilized in the control zone on streptavidin, forming a sandwich format. In the presence of the NS1 protein, it binds to the antibody and the aptamer-AuNP complex, producing a visible bichromatic line to indicate a positive result. The LFA detects DENV2 NS1 at concentrations as low as 5.2 ng/mL (95% CI: 4.6-5.8) in buffer. With a detection limit of 6.1 ng/mL (95% CI: 5.5-6.8) in spiked human serum, the test may offer a promising approach, pending further clinical evaluation approach for early dengue diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.